Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dishman Carbogen Amcis Limited (DCAL.NS)
Ahmedabad, IN
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segments: Contract Research and Manufacturing Services (CR&MS), and Marketable Molecules. Beyond its core services, it manufactures and distributes an extensive portfolio of products, including bulk drugs, chemical intermediates, various phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D derivatives, and fine chemicals. Additionally, its offerings encompass personal care products like hand and body washes, sanitizers, and antiseptics, as well as a range of pharmaceutical and cosmetic formulations, including generic and highly potent active pharmaceutical ingredients. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.32% | +19.28% | +24.96% | +16.24% | -10.96% | -14.42% | -3.71% | +60.21% | +9.47% | +38.80% | +291.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+8.1% ★ Q1'26: +18.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+2,861.9% ★ Q1'26: -49.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+2.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.6% ★ Q1'26: +8.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.4% ★ Q1'26: +2.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.6% ★ Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×5.48× Q1'26: 4.75× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.89B
est: 15.53B (+2.3%)
|
15.96B
est: 16.54B (-3.5%)
|
17.14B
est: 16.28B (+5.2%)
|
16.53B
est: 17.30B (-4.4%)
|
19.20B
est: 18.72B (+2.5%)
|
20.44B
est: 22.30B (-8.4%)
|
19.12B
est: 18.76B (+1.9%)
|
21.41B
est: 21.41B (+0.0%)
|
23.15B
est: 23.99B (-3.5%)
|
26.16B
est: 26.91B (-2.8%)
|
27.12B
est: 29.84B (-9.1%)
|
| EBITDA |
4.00B
est: 2.28B (+75.2%)
|
4.37B
est: 2.43B (+79.9%)
|
4.68B
est: 2.39B (+95.7%)
|
4.91B
est: 2.54B (+93.2%)
|
5.98B
est: 4.21B (+42.1%)
|
5.25B
est: 5.85B (-10.3%)
|
2.86B
est: 4.25B (-32.6%)
|
3.43B
est: 4.58B (-25.2%)
|
3.08B
est: 5.26B (-41.5%)
|
3.07B
est: 5.80B (-47.1%)
|
4.73B
est: 6.45B (-26.7%)
|
| EBIT |
2.49B
est: 252.28M (+886.6%)
|
3.02B
est: 268.63M (+1,022.9%)
|
2.55B
est: 264.51M (+862.3%)
|
2.80B
est: 280.95M (+895.3%)
|
3.58B
est: 2.66B (+34.4%)
|
2.42B
est: 3.95B (-38.7%)
|
-215.20M
est: 2.47B (-108.7%)
|
349.70M
est: 2.66B (-86.9%)
|
269.00M
est: 3.05B (-91.2%)
|
-22.90M
est: 3.37B (-100.7%)
|
1.79B
est: 4.67B (-61.7%)
|
| Net Income |
1.20B
est: 1.11B (+8.1%)
|
1.71B
est: 1.57B (+9.2%)
|
1.45B
est: 1.98B (-26.5%)
|
1.55B
est: 1.54B (+0.7%)
|
2.10B
est: 1.64B (+28.5%)
|
1.59B
est: 2.48B (-36.2%)
|
-1.65B
est: 1.73B (-195.5%)
|
180.10M
est: 1.86B (-90.3%)
|
-298.00M
est: 2.14B (-113.9%)
|
-1.53B
est: 2.36B (-165.0%)
|
32.40M
est: 1.96B (-98.3%)
|
| SGA |
553.60M
est: 2.42B (-77.1%)
|
568.30M
est: 2.58B (-78.0%)
|
740.90M
est: 2.54B (-70.8%)
|
508.40M
est: 2.70B (-81.1%)
|
782.70M
est: 8.40B (-90.7%)
|
791.60M
est: 11.33B (-93.0%)
|
850.30M
est: 9.41B (-91.0%)
|
1.02B
est: 10.15B (-90.0%)
|
1.36B
est: 11.65B (-88.3%)
|
12.16B
est: 12.85B (-5.4%)
|
4.44B
est: 5.43B (-18.1%)
|
| EPS |
7.43
est: 7.18 (+3.4%)
|
10.60
est: 10.16 (+4.3%)
|
9.01
est: 12.82 (-29.7%)
|
9.58
est: 9.95 (-3.7%)
|
13.03
est: 12.80 (+1.8%)
|
9.85
est: 13.97 (-29.5%)
|
-10.53
est: 0.30 (-3,610.0%)
|
1.15
est: 2.10 (-45.2%)
|
-1.90
est: 4.30 (-144.2%)
|
-9.79
est: 7.90 (-223.9%)
|
0.21
est: 12.50 (-98.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 41.6K | 0.65% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 9.0K | 0.56% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 460.8K | 0.07% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 52.8K | 0.46% |
| 5 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.00% | 7.5K | 0.49% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 119.6K | 0.39% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 108.7K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 66.5K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deohooti Janmejay Vyas | Whole Time Director | 12M | female |
| Arpit Janmejay Vyas | Global MD & Director | — | male |
| Dharmesh Desai | GM of Secretarial & Legal | — | male |
| Harshil R. Dalal | Global Chief Financial Officer | — | male |
| Himani S. Dhotre | Chief Executive Officer of Projects & Operations | — | — |
| Lucie Framinet | Marketing Manager | — | — |
| Martin Schneider | Chief Quality & Compliance Officer of CARBOGEN AMCIS | — | — |
| Paolo Armanino | Chief Operating Officer of Indian Operations | — | male |
| Alan Fischer | Chief Technology Officer of CARBOGEN AMCIS | — | — |
| Shrima Gaurangbhai Dave | Compliance Officer & Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DCAL.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
